Arterra Bioscience
Arterra Bioscience is a Naples-based biotech that develops plant cell culture-derived bioactive ingredients, in vitro bioassay services, and tissue models for cosmetics, pharmaceutical, nutraceutical, medical device, agriculture, and food industries, with a small DTC skincare line.
- Company typePublic
- Founded2004
- HeadquartersNapoli, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arterra Bioscience does
Arterra Bioscience S.p.A. is a Naples-based Italian biotechnology company founded in 2004 that develops plant cell culture-derived bioactive ingredients and contract research services for six end markets: agriculture, food, cosmetics, medical devices, pharmaceuticals, and nutraceuticals. Its core technology platform combines controlled-environment plant cell culture (in vitro plants, stem cells, and root cultures grown in flasks and bioreactors, from gram to ton scale), freeze-drying for stable preservative-free raw materials, a proprietary 100+ assay in vitro bioassay platform, recombinant protein expression across bacteria/yeast/insect/mammalian/plant systems, and 3D skin and intestinal tissue models for compound screening.
The company monetizes this stack through four complementary streams: (1) licensing and sale of proprietary plant cell extracts to cosmetics, pharmaceutical, and nutraceutical manufacturers, channeled through a joint venture (Vitalab S.r.l.) with Intercos S.p.A. — which also holds an 8.65% equity stake in Arterra — for branded skincare ingredients used in prestigious international cosmetics brands; (2) contract research services using the bioassay platform and tissue models for industrial and academic clients; (3) commercialization of active ingredients for medical devices via ADL Farmaceutici (since June 2021), including the ArterraBio Complex I product; and (4) a small direct-to-consumer e-commerce line selling 'Uno' and 'Due' skincare products at €25 per unit.
Arterra is publicly listed on Euronext Growth Milan (ticker formerly on AIM Italia since October 2019, IPO oversubscribed 7x), holds 25 patents and 69 scientific publications, maintains integrated ISO 9001/14001/45001 and EFfCI GMP certifications, and operates a team of 40-50 employees led by founder/CEO M. Gabriella Colucci alongside a researcher-heavy management including CSO Vincenzo Fogliano (Clarivate top-cited Agri-Food scientist since 2013). FY2025 revenue reached €4.6 million (+11.42% YoY).
Arterra Bioscience firmographics
Firmographics- Name
- Arterra Bioscience
- Legal name
- Arterra Bioscience S.p.A.
- Website
- https://arterrabio.it
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Arterra Bioscience is a Naples-based biotech that develops plant cell culture-derived bioactive ingredients, in vitro bioassay services, and tissue models for cosmetics, pharmaceutical, nutraceutical, medical device, agriculture, and food industries, with a small DTC skincare line.
- Ownership category
- akta.pro rank
Arterra Bioscience industry classification
Industry- Product category
- Biotechnology Ingredients
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
- akta.pro secondary industries
- Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK), Herbal & Botanical Supplements (CRADAGAD)
Keywords
Where Arterra Bioscience is headquartered
LocationHeadquarters
- HQ city
- Napoli
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Arterra Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Active Ingredient Licensing and Sales: Licensing and sale of proprietary plant cell extracts and active ingredients to cosmetics, pharmaceutical, and nutraceutical companies. Ingredients are used in finished products by clients like Vitalab and through partnerships with Intercos.
- Contract Research Services: Fee-for-service research collaborations with industrial partners and academic institutions, including screening services using proprietary bioassay platforms and product validation studies.
- Direct Consumer Product Sales: Direct-to-consumer sales of branded skincare products through the company's e-commerce platform, including 'Uno' and 'Due' product lines priced at €25 per unit.
- Medical Device Component Sales: Sale of active ingredients and formulations for medical devices through partnership with ADL Farmaceutici, including ArterraBio Complex I for medical devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Uno skincare product - Daily Youth Defense cream |
| Unit Pricing | Pay-as-you-go | Due skincare product |
| Other | Multi-year contract | B2B active ingredients and contract research |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Arterra Bioscience product offering
Product offeringCore offering
Arterra Bioscience develops and manufactures standardized bioactive ingredients derived from proprietary plant cell cultures, leveraging a 100+ in vitro bioassay platform to identify and validate actives for cosmetics, pharmaceuticals, nutraceuticals, medical devices, agriculture, and food. The company supplies these ingredients under licensing/sales agreements to industrial clients, performs fee-for-service contract research, and sells a small line of branded skincare products (Uno, Due) direct-to-consumer at €25 per unit.
Product overview
Arterra Bioscience operates as a biotechnology company offering a portfolio of research services and consumer products. The research services include an In Vitro Bioassay Platform (100+ assays), Plant Cultures, Intestine In Vitro Models, Skin In Vitro/Ex Vivo Models, and Recombinant Protein Expression services. Consumer products include the skincare line UNO and Due (DAILY YOUTH DEFENSE) sold through the online shop. Additionally, through its joint venture Vitalab, the company offers cosmetic ingredient sub-brands used in prestigious skincare products. The company also supplies bioactive ingredient complexes like ArterraBio Complex I for medical devices.
Differentiator
Problem solved
Functional benefit
Brands
- Vitalab: Joint venture brand with Intercos S.p.A. for cosmetic active ingredients and skincare products. Present in prestigious skincare and make-up brands. Website: www.vitalabactive.com
- Vitalabactive
Products and services
- Uno (Daily Youth Defense) A nutrient-rich skincare cream enriched with natural peptides that stimulate cellular metabolism and microcirculation, providing hydration, nutrition and a rejuvenated complexion. Sold direct-to-consumer via the Arterra online shop at €25 per unit including VAT, targeting individual skincare consumers seeking biotech-derived actives.
- Due A skincare product priced at €25 per unit including VAT, available for purchase online through the Arterra online shop alongside the Uno cream. Targets end-consumers seeking biotech-derived skincare based on Arterra's plant-cell culture actives.
- In Vitro Bioassay Services Fee-for-service screening using Arterra's proprietary 100+ in vitro bioassay platform covering gene synthesis, key proteins in cellular processes, enzyme activities, metabolic processes and different physiological states of cells. Used to identify effects of actives for industrial partners across agriculture, food, cosmetics, medical devices, pharmaceuticals and nutraceuticals.
- Plant Cell Culture Production Services Industrial-scale supply of plant cell cultures and extracts from in vitro plants, stem cells and root cultures grown in flasks and bioreactors. Used to produce specific secondary metabolites for cosmetics, medical devices and nutraceutical applications, with gram-to-ton scalability via freeze-drying technology.
- Intestine In Vitro Model Screening Services In vitro intestinal models using co-cultures of different human cell lines to reproduce differentiated intestinal epithelium, used for simulating inflammatory processes and screening compounds for intestinal health applications. Targets medical device, pharmaceutical and nutraceutical customers.
- 3D Skin and Ex Vivo Skin Assay Services Ex vivo assay platform based on manipulation of skin explants with cryopreservation and analysis capabilities, plus 3D reconstituted skin models simulating pathological inflammatory processes such as atopic dermatitis. Applied to cosmetics, medical device and pharmaceutical customers.
- Recombinant Protein Expression Services Recombinant protein expression in bacteria, yeasts, insect cells, mammalian cells and plant cells, including stable expression in plant cell cultures and transient expression via agro-infiltration for molecular farming applications. Includes production of extremozymes from extremophilic bacteria in tomato cells for food processing.
- ArterraBio Complex I for Medical Devices A proprietary bioactive ingredient complex for medical device applications, commercialized through ADL Farmaceutici (partnership active since June 2021), along with new raw materials co-developed for the nutraceutical and medical device sectors.
Quantifiable outcome
- Revenue growth of 11.42% YoY reaching €4.6 million in 2025
- +2 more outcomes
Companies that use Arterra Bioscience
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles5 records
Arterra Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Arterra Bioscience partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Isagro S.p.A.coreLong-standing research partnership since 2004 for agricultural biotechnology solutions. Development of solutions to improve nutrient assimilation and plant defense against insects and pathogenic microorganisms. Isagro is now owned by Gowan Company, L.L.C.
- Intercos S.p.A.coreDevelopment of cosmetic ingredients and partner of the joint venture Vitalab. Collaboration for innovative cosmetic active ingredient development. Intercos holds 8.65% equity stake in Arterra.
- Vitalab s.r.l.coreJoint venture for development and licensing of cosmetic ingredients and branded skincare products. License agreement for commercializing plant cell culture extracts under Vitalab brand in prestigious international markets.
- ADL Farmaceutici s.r.l.coreMarketing partnership for commercialization of ArterraBio Complex I for medical devices and development of new raw materials in the nutraceutical sector for medical devices. Active since June 2021.
- Montecarlofruit S.a.r.l.minorResearch project on mango by-products in the food sector. Circular economy approach to valorize agricultural waste streams.
- Wageningen University & ResearchcoreResearch collaboration in cosmetics and nutraceutics fields. Prof. Vincenzo Fogliano serves as Director of Food Quality & Design Department at Wageningen University and part-time Research Coordinator at Arterra.
- University of Naples Federico IIcoreCo-financing of PhD programs in Science and Technology of agro-food productions and Materials and Structural Engineering. Research projects in cosmetics and nutraceutics.
- CRB SA (Biocosmetic Research Center)minorCo-development of innovative cosmetic active ingredients for skin care. Co-owner of patent MI2009A 000905 for Rubus cell culture extracts.
- ENEA (National Agency for New Technologies)minorResearch collaboration in the cosmetics field through InnCoCells project for innovative cosmetic products from plants and plant cells.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Arterra Bioscience competitors and assessment
Company assessmentBroad incumbents
- Givaudan: Swiss fragrance and beauty major with expanding active ingredients division including biotech and natural actives. Increasingly overlapping with Arterra's cosmetic actives business as it moves into prestige skincare.
- DSM-Firmenich: Global nutrition, health, and beauty ingredients major with botanical and biotech actives for personal care and nutraceuticals. Competes in same end markets with much broader portfolio and global distribution.
- Sederma (Croda Beauty): Croda subsidiary producing bioactive cosmetic ingredients including peptides and plant-derived actives. Larger incumbent with overlapping bioactives portfolio for skincare applications.
- Evonik Industries: German specialty chemicals giant with significant cosmetic and nutraceutical ingredient portfolio including biotech-derived actives. Overlaps with Arterra in specialty cosmetic actives but operates at vastly larger scale across many industries.
Direct peers
- Mibelle Biochemistry: Swiss producer of plant cell culture extracts and bioactive ingredients for cosmetics and nutraceuticals. Direct competitor in plant cell-derived cosmetic actives with similar B2B ingredient licensing model.
- Euromed: Spanish producer of standardized botanical extracts for pharma, nutraceutical, and cosmeceutical markets. Comparable in standardized botanical actives for regulated health applications.
- Provital Group: Spanish specialty ingredients company focused on plant-based cosmetic active ingredients. Similar B2B model supplying cosmetic formulators with bioactive ingredients derived from botanical sources.
- Naolys: French biotech specializing in plant cell culture for cosmetic active ingredients. Directly comparable technology platform (undifferentiated plant cells for skincare actives) and customer base (prestigious cosmetic brands).
- Indena: Italian company producing botanical active ingredients for pharmaceutical, nutraceutical, and cosmetic applications. Closely comparable in geography (Italy), botanical extraction focus, and multi-vertical ingredient licensing.
- Active Concepts: US-based supplier of specialty cosmetic active ingredients including plant-derived and biotechnology-based materials. Comparable as a specialty cosmetic ingredient supplier serving prestige beauty brands.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Arterra Bioscience social profiles
Digital presenceArterra Bioscience compliance and trust
Trust signalCompliance7 records
Arterra Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arterra Bioscience leadership team
Management profileNumber of profiles
Profiles8 records
Arterra Bioscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Arterra Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arterra Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arterra Bioscience
What does Arterra Bioscience do?
Arterra Bioscience develops and manufactures standardized bioactive ingredients derived from proprietary plant cell cultures, leveraging a 100+ in vitro bioassay platform to identify and validate actives for cosmetics, pharmaceuticals, nutraceuticals, medical devices, agriculture, and food. The company supplies these ingredients under licensing/sales agreements to industrial clients, performs fee-for-service contract research, and sells a small line of branded skincare products (Uno, Due) direct-to-consumer at €25 per unit.
Is Arterra Bioscience a public or private company?
Arterra Bioscience is a public company. It is classified as public and is currently operating.
When was Arterra Bioscience founded?
Arterra Bioscience was founded in 2004. It employs 11 to 50 people.
Where is Arterra Bioscience based?
Arterra Bioscience is headquartered in Napoli, Italy, in the Europe region.
How does Arterra Bioscience make money?
Four revenue lines are on record. Active Ingredient Licensing and Sales are the primary driver. The others are contract Research Services, direct Consumer Product Sales and medical Device Component Sales.
Who are Arterra Bioscience's main competitors?
Broad incumbents on record are Givaudan, DSM-Firmenich, Sederma (Croda Beauty) and Evonik Industries. Direct peers are Mibelle Biochemistry, Euromed, Provital Group, Naolys, Indena and Active Concepts.
Does Arterra Bioscience have an API?
No public API is recorded for Arterra Bioscience.
What industry is Arterra Bioscience in?
Arterra Bioscience's product category is Biotechnology Ingredients. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of AFAJAKAK, Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin). Its NAICS code is 325411 and its SIC code is 2833.